Lotus Pharmaceutical's (TPE:1795) subsidiary, Lotus International, will reduce its capital by $70 million, according to a Wednesday filing with the Taiwan Exchange.
The reduction involves the cancellation of 70 million shares as part of the group's capital utilization plan.
Following the reduction, Lotus International's share capital will stand at $16.1 million.